Luminal B breast tumors are not HER2 positive.
作者信息
Bhargava Rohit, Dabbs David J
出版信息
Breast Cancer Res. 2008;10(5):404; author reply 405. doi: 10.1186/bcr2134. Epub 2008 Sep 26.
Abstract
摘要
相似文献
1
Luminal B breast tumors are not HER2 positive.管腔B型乳腺肿瘤不是HER2阳性。
Breast Cancer Res. 2008;10(5):404; author reply 405. doi: 10.1186/bcr2134. Epub 2008 Sep 26.
2
HER2 as a prognostic factor in breast cancer.HER2作为乳腺癌的一个预后因素。
Oncology. 2001;61 Suppl 2:67-72. doi: 10.1159/000055404.
3
4
Evaluation of oestrogen and progesterone receptors, and c-erbB-2 in carcinoma of the breast in Trinidadian women.特立尼达女性乳腺癌中雌激素和孕激素受体以及c-erbB-2的评估。
West Indian Med J. 2002 Mar;51(1):4-9.
5
6
Prognostic significance of molecular classification of breast invasive ductal carcinoma.乳腺浸润性导管癌分子分类的预后意义
Arch Gynecol Obstet. 2009 Jul;280(1):43-8. doi: 10.1007/s00404-008-0867-1. Epub 2008 Dec 11.
7
Correspondence re: Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000;13:37-45.
Mod Pathol. 2001 Mar;14(3):263. doi: 10.1038/modpathol.3880297.
8
9
The quality of Her-2/Neu predictive immunohistochemistry: something FISHy?Her-2/Neu预测性免疫组织化学的质量：有点像鱼腥味的事？ （此翻译仅供参考，具体含义需结合专业背景进一步理解，原标题可能是带有一定双关或隐喻的表述）
Mod Pathol. 2000 Jan;13(1):1-3. doi: 10.1038/modpathol.3880001.
10
HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.通过荧光原位杂交和免疫组织化学检测纯导管原位癌以及浸润性导管癌的导管内和浸润成分中的HER2状态。
Histopathology. 2006 May;48(6):702-7. doi: 10.1111/j.1365-2559.2006.02403.x.
引用本文的文献
1
The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer.持续探索乳腺癌中 CDK4/6 抑制剂应答的生物标志物。
Mol Cancer Ther. 2020 Jan;19(1):3-12. doi: 10.1158/1535-7163.MCT-19-0253.
2
Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers.由雌激素受体/孕激素受体/人表皮生长因子受体2亚型定义的乳腺癌生存率以及根据肿瘤分级和免疫组化生物标志物的替代分类
J Cancer Epidemiol. 2014;2014:469251. doi: 10.1155/2014/469251. Epub 2014 May 26.
3
Hypothesized role of pregnancy hormones on HER2+ breast tumor development.妊娠激素对 HER2+ 乳腺癌肿瘤发展的假设作用。
Breast Cancer Res Treat. 2013 Jan;137(1):237-46. doi: 10.1007/s10549-012-2313-0. Epub 2012 Nov 8.
4
A Comparative Analysis of Biomarker Expression and Molecular Subtypes of Pure Ductal Carcinoma In Situ and Invasive Breast Carcinoma by Image Analysis: Relationship of the Subtypes with Histologic Grade, Ki67, p53 Overexpression, and DNA Ploidy.通过图像分析对纯导管原位癌和浸润性乳腺癌的生物标志物表达及分子亚型进行比较分析：各亚型与组织学分级、Ki67、p53过表达及DNA倍体的关系
Int J Breast Cancer. 2011;2011:217060. doi: 10.4061/2011/217060. Epub 2011 Aug 17.
5
Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients.980例中国乳腺癌患者雄激素受体的表达及其与分子亚型的相关性
Breast Cancer (Auckl). 2012;6:1-8. doi: 10.4137/BCBCR.S8323. Epub 2011 Dec 6.
6
Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.同时存在的导管原位癌独立预测淋巴结阳性的腔型乳腺癌肿瘤侵袭性较低。
Med Oncol. 2012 Sep;29(3):1536-42. doi: 10.1007/s12032-011-0082-y. Epub 2011 Oct 8.
7
Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study.中国女性乳腺癌分子亚型的独特分布及其预后意义：一项基于人群的队列研究。
BMC Cancer. 2011 Jul 12;11:292. doi: 10.1186/1471-2407-11-292.
本文引用的文献
1
Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.导管原位癌与浸润性乳腺癌分子表型的比较。
Breast Cancer Res. 2008;10(4):R67. doi: 10.1186/bcr2128. Epub 2008 Aug 5.
2
Histopathologic variables predict Oncotype DX recurrence score.组织病理学变量可预测Oncotype DX复发评分。
Mod Pathol. 2008 Oct;21(10):1255-61. doi: 10.1038/modpathol.2008.54.
3
Molecular classification of breast tumors: toward improved diagnostics and treatments.乳腺肿瘤的分子分类：迈向更精准的诊断与治疗
Methods Mol Biol. 2007;360:91-114. doi: 10.1385/1-59745-165-7:91.
4
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.《卡罗来纳乳腺癌研究中的种族、乳腺癌亚型与生存率》
JAMA. 2006 Jun 7;295(21):2492-502. doi: 10.1001/jama.295.21.2492.
5
HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring.采用免疫组织化学分析和荧光原位杂交技术检测乳腺癌中的HER-2：2279例单机构经验及双色与单色评分比较
Am J Clin Pathol. 2004 May;121(5):631-6. doi: 10.1309/VE78-62V2-646B-R6EX.
6
Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay.存档石蜡包埋组织中基因表达的测量：一种92基因逆转录-聚合酶链反应检测方法的开发与性能
Am J Pathol. 2004 Jan;164(1):35-42. doi: 10.1016/S0002-9440(10)63093-3.
7
Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma.浸润性乳腺癌雌激素受体免疫组化染色结果一致时所需的最短福尔马林固定时间。
Am J Clin Pathol. 2003 Jul;120(1):86-92. doi: 10.1309/QPHD-RB00-QXGM-UQ9N.
8
Estrogen receptor analysis in primary breast tumors by ligand-binding assay, immunocytochemical assay, and northern blot: a comparison.
Breast Cancer Res Treat. 2001 Jun;67(3):263-71. doi: 10.1023/a:1017946810277.
9
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.乳腺癌的基因表达模式可区分具有临床意义的肿瘤亚类。
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74. doi: 10.1073/pnas.191367098.
10
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.通过免疫组织化学检测雌激素受体状态在预测乳腺癌辅助内分泌治疗反应方面优于配体结合测定法。
J Clin Oncol. 1999 May;17(5):1474-81. doi: 10.1200/JCO.1999.17.5.1474.
Zotero 插件